3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR

Drug Discovery Today

Volumn 18, Issue 11-12, 2013, Pages 574-581

  Wu, Baojian ^a   Li, Sha ^a   Dong, Dong ^b  

^a JINAN UNIVERSITY   (China)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CLOTRIMAZOLE; CONSTITUTIVE ANDROSTANE RECEPTOR; ESTRADIOL; HYPERFORIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PACLITAXEL; PHENOBARBITAL; PREGNANE X RECEPTOR; PREGNANEDIONE; RIFAMPICIN; SR 12813; TAMOXIFEN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ALPHA HELIX; BETA SHEET; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; DETOXIFICATION; HUMAN; LIGAND BINDING; LIGAND BINDING DOMAIN; MOLECULAR WEIGHT; NONHUMAN; PHARMACOPHORE; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID;

EID: 84878862550     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.01.001     Document Type: Review

References (44)

1. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 1988 889 895
2. R.M. Evans The nuclear receptor superfamily: a rosetta stone for physiology Mol. Endocrinol. 19 2005 1429 1438
3. T. Chen Nuclear receptor drug discovery Curr. Opin. Chem. Biol. 12 2008 418 426
4. Y. Shi Orphan nuclear receptors in drug discovery Drug Discov. Today 12 2007 440 445
5. J.T. Moore The nuclear receptor superfamily and drug discovery Chem. Med. Chem. 1 2006 504 523
6. Y. Wang Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1 Mol. Endocrinol. 25 2011 2041 2053
7. R. Kumar, and E.B. Thompson The structure of the nuclear hormone receptors Steroids 64 1999 310 319
8. J. Gao, and W. Xie Targeting xenobiotic receptors PXR and CAR for metabolic diseases Trends Pharmacol. Sci. 33 2012 552 558
9. J. Cunningham, and D. Zehnder New vitamin D analogs and changing therapeutic paradigms Kidney Int. 79 2011 702 707
10. A.H. Tolson, and H. Wang Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR Adv. Drug Deliv. Rev. 62 2010 1238 1249
11. J. Fan Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha, 25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer J. Pharmacol. Exp. Ther. 330 2009 389 402
12. E.C. Chow 1α,25-Dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo J. Pharmacol. Exp. Ther. 337 2011 846 859
13. M. Niemi Pharmacokinetic interactions with rifampicin: clinical relevance Clin. Pharmacokinet. 42 2003 819 850
14. T.M. Willson, and S.A. Kliewer PXR, CAR and drug metabolism Nat. Rev. Drug Discov. 1 2002 259 266
15. Nuclear Receptors Committee A unified nomenclature system for the nuclear receptor superfamily Cell 97 1999 161 163
16. X. Ma The pregnane X receptor: from bench to bedside Expert Opin. Drug Metab. Toxicol. 4 2008 895 908
17. A. di Masi Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects Mol. Aspects Med. 30 2009 297 343
18. R.E. Watkins The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity Science 292 2001 2329 2333
19. R.X. Xu A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer Mol. Cell 16 2004 919 928
20. N. Rochel The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand Mol. Cell 5 2000 173 179
21. K. Suino The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization Mol. Cell 16 2004 893 905
22. A. Ueda Residue threonine 350 confers steroid hormone responsiveness to the mouse nuclear orphan receptor CAR Mol. Pharmacol. 61 2002 1284 1288
23. S.A. Kliewer The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism Endocr. Rev. 23 2002 687 702
24. Z. Dvorak Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition Toxicol. Lett. 202 2011 129 132
25. Y. Xue Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition Mol. Endocrinol. 21 2007 1028 1038
26. H. Kojima Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays Toxicology 280 2011 77 87
27. S. Ekins Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR PLoS Comput. Biol. 5 2009 e1000594
28. Y. Cheng, and M.R. Redinbo Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721 Protein Sci. 20 2011 1713 1719
29. S. Ekins, and J.A. Erickson A pharmacophore for human pregnane X receptor ligands Drug Metab. Dispos. 30 2002 96 99
30. S. Ekins Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites Mol. Pharmacol. 72 2007 592 603
31. R.E. Watkins 2.1 Å crystal structure of human PXR in complex with the St. John's wort compound hyperforin Biochemistry 42 2003 1430 1438
32. J.E. Chrencik Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin Mol. Endocrinol. 19 2005 1125 1134
33. C. Carlberg Vitamin D receptor ligands: the impact of crystal structures Expert Opin. Ther. Pat. 22 2012 417 435
34. G. Tocchini-Valentini Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands Proc. Natl. Acad. Sci. U. S. A. 98 2001 5491 5496
35. G. Tocchini-Valentini Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification J. Med. Chem. 47 2004 1956 1961
36. G. Eelen Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction Mol. Pharmacol. 67 2005 1566 1573
37. S. Hourai Structure-based design of a superagonist ligand for the vitamin D nuclear receptor Chem. Biol. 15 2008 383 392
38. S. Hourai Probing a water channel near the A-ring of receptor-bound 1 alpha, 25-dihydroxyvitamin D3 with selected 2 alpha-substituted analogues J. Med. Chem. 49 2006 5199 5205
39. Y. Xue Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism Bioorg. Med. Chem. 15 2007 2156 2166
40. R.E. Watkins Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor J. Mol. Biol. 331 2003 815 828
41. F. Molnár 1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor PLoS ONE 6 2011 e18124
42. L. Verlinden Synthesis, structure, and biological activity of des-side chain analogues of 1α,25-dihydroxyvitamin D3 with substituents at C18 Chem. Med. Chem. 6 2011 788 793
43. P. Antony Structure-function relationships and crystal structures of the vitamin D receptor bound 2 alpha-methyl-(20S,23S)- and 2 alpha-methyl-(20S,23R)- epoxymethano-1 alpha, 25-dihydroxyvitamin D3 J. Med. Chem. 53 2010 1159 1171
44. P. Gouet, and E. Courcelle ENDscript: a workflow to display sequence and structure information Bioinformatics 18 2002 767 768